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ABSTRACT  
VISUAL FUNCTION FOLLOWING OPTIC NEURITIS TREATMENT 
 
AIM: 
To evaluate visual function following optic neuritis treatment in South India. 
 
MATERIALS AND METHODS: 
 This is a prospective study carried out over a period of 13 months , 98 eyes 
were examined and followed up for 3 months. Visual function following treatment 
was assessed. 
RESULTS: 
Mean age was 40.0 years. Male preponderance was seen (53.4%).  Papillitis           
(65.3%) was more common than retrobulbar neuritis (34.7%). Bilateral 
presentation was seen in 20.3%. Baseline median logMAR visual acuity was 1.48 
which improved to 0.3 a t 1 month follow up. Approximately 78% of eyes showed  
significant improvement in visual acuity. Other visual function including colour 
vision, central fields, Brightness sensitivity and red desaturation showed 
statistically significant improvement following treatment. Only 3 patients in our 
study showed signs of associated demyelination. 
 CONCLUSION: 
   Visual function following treatment showed a good recovery. There was 
less incidence of associated demyelinating disease in our study. 
KEYWORDS:  
Optic neuritis, visual acuity, central fields, dyschromatopsia, brightness 
sensitivity, red desaturation,  demyelination. 
 
 
INTRODUCTION  
Optic neuritis is an infective, inflammatory or demyelinating 
disease  affecting the optic nerve.  It is characterised by sudden loss of 
vision often accompanied by pain which can be lasting for several hours 
or days followed by gradual recovery. Women are more commonly 
affected than men than men. Most of the cases are idiopathic and it can 
also be associated with multiple sclerosis. It is the most common   
demyelinating disease causing optic neuritis. Other common  causes 
include infectious, parainfectious , inflammatory, paravaccination and 
immunological responses. 
 
Optic neuritis can be typical (associated with multiple sclerosis)  
presents as acute uniocular vision loss often associated with pain that 
worsens on eye movements. RAPD is present in almost all unilateral 
cases. Variety of field defects and dyschromatopsia is noted in affected 
eyes. Recovery of vision usually begins within the first month. It 
improves independent of steroids. Atypical optic neuritis includes 
absence of pain , marked swelling of optic nerve with retinal exudates 
and haemorrhages. Patients with atypical features of neuritis are at lower 
risk of developing multiple sclerosis.   
 
 
An episode of optic neuritis increases the risk of developing 
multiple sclerosis. Optic neuritis is referred to as   Mono symptomatic or 
Idiopathic   or as a Clinically Isolated Syndrome in the absence of  signs 
of  multiple sclerosis. 
The clinical triad of optic neuritis consist of 
1. Visual loss 
2.  Periocular pain 
3. Dyschromatopsia. 
 
 Decreased vision associated with pain on eye movements is most 
common in retrobulbar optic neuritis. Pain may occur due to traction of 
origins of the medial and superior recti on optic nerve sheath at the orbital 
apex. (Whitnall’s hypothesis) 1. 
 
Other aspects of visual function such as colour vision, contrast 
sensitivity, and visual field are affected. Visual field defects are variable 
in patients with optic neuritis which ranges from diffuse depression, 
centrocaecal scotoma to quadrantic defects and altitudinal defects. Optic 
neuritis is not recovered completely.2,47 
 
 
Rapid recovery of vision occurs with the use of corticosteroids and 
it is the main stay of treatment. There are reports that even after six to 
twelve months there is not much difference in visual outcome. A pulse 
therapy of intravenous methyl prednisolone in a dose of  500mg  twice a 
day was given for 3 consecutive days followed by oral steroids of 1mg / 
kilogram body weight  was given for 11 days is given. 
 
The gold standard treatment for Optic neuritis is based on Optic 
Neuritis Treatment Trial. It was undertaken to determine the efficacy of 
corticosteroids which enrolled 455 patients between 1988 and 1991. 
ONTT evaluated the efficacy of corticosteroid treatment for acute optic 
neuritis and relationship between optic neuritis and multiple sclerosis. 
  
 
 
REVIEW OF LITERATURE 
HISTORY: 
Optic neuritis was first described by Nettleship in 1884. Gunn in 
1891 defined optic neuritis as rapid failure of visual acuity usually more 
marked in one eye.  Buning et al indicated that there is no correlation 
between initial visual acuity or treatment and residual visual function 
disturbances.  Uthoff 1904 described a component of interstitial 
inflammation in the connective tissue septa along with demyelination of 
optic nerve. 2,3,4   
 
Morphologically  it is classified into 
1. Papillitis – associated with swollen optic disc . 
2. Retrobulbar neuritis -  disc appears normal. 
3. Neuroretinitis –  inflammation of  nerve fibre layer and macular 
star in late stages. 
Isolated optic neuritis is referred as with absence signs of multiple 
sclerosis or any systemic diseases. 
 
 
 
Severity of vision loss can vary from slight deficit to complete loss 
of light perception. Even if the visual recovery is complete few may have 
abnormalities found in contrast sensitivity, colour vision,  stereopsis  and 
optic disc appearance.1 
 
ON can occur in isolation or in association with multiple sclerosis.5   
Women are most commonly affected than men. 
 
The gold standard treatment for optic neuritis is based on the Optic 
Neuritis Treatment Trial which was to determine the efficacy of 
corticosteroids and to permit long term analysis. 
                  
  
 
 
ANATOMY OF OPTIC NERVE 
It is a second cranial nerve. It extends from optic disc and upto 
optic chiasma. It is the backward continuation of the nerve fibre layer of 
the retina which consist of axons originating from ganglion cells. It also 
contains light reflex fibres and some centrifugal fibres. It is surrounded 
by meninges. 
 
The optic nerve fibres are about million, 2-10 microns in diameter. 
It is about fifty millimeters in length. 
 
 It is divided into four parts 
 Intraocular part (1mm) 
 Intraorbitalpart  (30mm) 
 Intracanalicularpart  (6-9mm) 
 Intracranial part  (10mm) 
 
 
 
 
 
 
 
INTRAOCULAR PART 
Optic nerve pass through sclera, choroid and finally appears in the 
eye as optic disc. The average diameter of this part is 1.5mm, it expands 
3mm behind the sclera where the neurons acquire a myelin sheath. It is 
divided into four layers from anterior to posterior. 
 
1. Surface nerve fibre layer: 
It is essentially composed of axonal bundles i.e nerve fibres of 
retina(94%)which converge on optic disc and astrocytes(5%).  The 
optic  disc covered by thin layer of astrocytes.the internal limiting 
membrane of Elschnig, which  seperates it from vitreous and is 
continuous with the internal limiting membrane of retina. The 
central portion of this membrane thickened known as centfral 
meniscus of Kuhnt. All the layers of retina apart from nerve fibre 
layer near the optic nerve are separated by partial rim of glial tissue 
called intermediate tissue of Kuhnt. 
 
 
 
 
 
 
2. Prelaminar region: 
The predominant structure at this level are neurons and 
significantly increased quantity seperates of astroglial tissue. The 
border tissue of Jcoby seperates the nerve from choroid. 
 
3. Lamina cribrosa: 
It is a fibrillar sieve like structure made up of fenestrated sheets of 
scleral connective tissue lined by glial tissue. It bridges the scleral 
canal. The bundle of optic nerve fibres leave the through these 
fenestrations. The border tissue of  Elschnig intervenes between the 
choroid and sclera and optic nerve fibres. It gets its rich blood 
supply from Circle of Zinn. 
 
4. Retrolaminar region: 
It is characterised by a decrease in astrocytes and acquisition of 
myelin that is supplied by oligodendrocytes. The addition of 
myelin sheath doubles the diameter of optic nerve. 
 
 
 
 
 
INTRAORBITAL PART: 
It starts from eyeball to optic foramen. It is covered by dura, 
arachnoid, pia. The pial sheath contains capillaries and sends septae to 
divide the nerve into fasciculi. The subarachnoid space contains 
cerebrospinal fluid. The central retinal artery along with its vein crosses 
the subarachnoid space to enter the nerve on its inferomedial part. 
Anteriorly nerve is separated from extraocular muscles by the orbital fat. 
Posteriorly optic nerve is surrounded by annulus of Zinn and  orgin of 
four rectus muscles. Some fibres of superior rectus muscle and medial 
rectus muscle are adhered to optic nerve sheath and accounts for pain on 
ocular movements seen in retrobulbar neuritis. The long and short ciliary 
nerves and arteries surround the optic nerve before these enter the 
eyeball. 
 
INTRACANALICULAR PART: 
It is in close relation to ophthalmic artery where the nerve crosses 
inferiorly from medial to lateral side in the dural sheath and then leaves 
the sheath at the orbital end of the canal. Medially sphenoid and posterior 
ethmoidal sinuses are separated by a thin bony lamina. 
 
 
 
INTRACRANIAL PART: 
In this part  it is about 1 cm in length. It lies above the cavernous 
sinus where the two nerves meet to form the chiasma. It is ensheathed in 
piamater but receives arachnoid and dural sheaths at the point of its entry 
into optic canal.  
 
ARRANGEMENT OF NERVE FIBRES: 
1. In the optic nerve head: Peripheral retinal fibres lie deep in retina. It 
occupies the superficial part of optic disc. Fibres which are present 
close to the ON head lie superficially in the retina and occupies more 
deep portion of the disc. 
 
THICKNESS OF NFL AT THE DISC: 
It progressively increases around different quadrants of optic disc 
margin 
 Most lateral quadrant (thinnest) 
 Upper temporal and lower temporal quadrant 
 Most medial quadrant 
 Upper nasal and lower nasal quadrant(thickest) 
 
 
 
2. In the distal region: The upper temporal and lower temporal fibres are 
situated on the temporal half of the optic nerve and are separated from 
each other by a wedge shaped area occupied by the papillomacular 
bundle. 
3.  In the proximal region: 
The macular fibres are centrally placed. 
 
VASCULAR SUPPLY OF OPTIC NERVE: 
1. Optic nerve head: 
a. Surface nerve fibre layer:  Its mainly supplied by capillaries 
derived from retinal arterioles. It anastomose with vessels of 
prelaminar region. Occasionally ciliary derived vessel from 
prelaminar region may enlarge to form cilioretinal artery. 
b.  The prelaminar region:  It is primarly derived from peripapillary 
choroidal  system or separate branches of short posterior ciliary 
arteries. 
c.  The lamina cribrosa region:  It is supplied by ciliary vessels which 
are derived from short posterior ciliary arteries and arterial circle of 
Zinn –Haller. 
 d.  The retrolaminar region: It is supplied by both ciliary and retinal 
circulation. The central retinal artery provides centripetal branches 
where it arisesfrom pial plexus and also centrifugal branches. 
 
 
 
 
2. The intraorbitalpart : Its supplied by two system of vessels. 
a. Periaxial : It is derived from six branches of internal carotid 
artery. 
1. Ophthalmic artery 
2. Long posterior ciliary arteries 
3. Short posterior ciliary arteries 
Fig 1 Blood Supply Of Optic Nerve Head 
 
 
4. Lacrimal artery 
5. Central artery of retina 
 
b. Axial system: It is derived from 
1. Intra neural branches of central retinal artery. 
2. Central collateral arteries which comes from central retinal 
artery. 
3.  Central artery of optic nerve. 
 
3. The inracanalicular part: 
It is supplied only by periaxial system of vessels. The pial plexus in 
this part is mainly fed from branches of ophthalmic artery. 
 
4. The intracranial part:  
It is exclusively supplied by periaxial system of vessels. The pial 
plexus is contributed by 4 sources  
1. Branches from internal carotid artery directly or through 
recurrent branch of anterior hypophsealartey 
2. Branches from anterior cerebral artery 
3. Small recurrent branches from ophthalmic artery 
4. Twigs from anterior communicating artery. 
 
 
DEMOGRAPHY: 
Most of the following information of visual outcome in optic 
neuritis comes from ONTT/LONS. The annual incidence of optic neuritis 
has been estimated in population based studies to be 1-5 per 1000,000.6  
Most patients are between ages of 20-50 years. Females are commonly 
affected than males. In ONTT, 77% were female, 85% were Caucasian 
and the mean age was 32±7 years.5 . Optic neuritis can occur at any age.  
In Asia, ON is more common in relation to the incidence of MS in the 
United States of America or Western Europe.8 
 
CLASSIFICATION: 
Optic neuritis is classified into 4 types based on site of involvement 
1. Retrobulbar neuritis – normal  appearance of disc. 
2. Papillitis –  swollen optic disc 
3. Perineuritis- its involvement of optic nerve sheath. 
4. Neuroretinitis  -   papillitis associated with inflammation of nerve 
fibre layer and  macular star in late stages. 
 
 
 
 
 
Fig  1. Papillitis – marked inflammation of the optic disc 
 
 
Fig 2 Retrobulbar neuritis- normal looking disc. 
 
 
 
 
Fig 3  Neuroretinitis-  marked inflammation around the optic disc 
with involvement of adjoining retina 
 
Based on topography, three principle type of neuritis is classified into 
1) Perineuritis or periaxial neuritis 
2) Axial neuritis 
3) Transverse neuritis 
 
 
 
 
 
 
 
ETIOLOGY 
 It is idiopathic in majority of cases. It could be  associated with 
demyelinating lesion, of which most common cause is multiple sclerosis.  
Other diseases known to cause optic neuritis are: 
 
 
 
 
 
 
A) Viral infections (e.g. chicken pox, measles, mumps etc.) 
B) Granulomatous infections such as tuberculosis, cat scratch disease, 
syphilis, Lyme disease or Cryptococcal meningitis. 
C) Autoimmune diseases like SLE, Wegner ’s Granulamatosis or 
sarcoidosis 
D) Contagious inflammation from orbit, meninges and sinuses 
E) Intraocular  inflammation  involving  retina, uvea, sclera. 
  
 
 
MULTIPLE SCLEROSIS AND OPTIC NEURITIS 
 Optic neuritis is the most common initial manifestation of multiple 
sclerosis. Most common cause of visual disability among young and 
middle aged adults.  MS is an acquired, chronic inflammatory disease of 
central nervous system. It is characterised by focal demyelinating lesions 
of varying age. It is reported to be most common aetiology  in Western 
literature.8,9  Incidence of MS in India and other Asian countries is 
low.10,11,12 
After an attack of optic neuritis, possibility of developing MS 
reaches 38% in following 10 years and the percentage rises to 56% if 
there are brain abnormalities in MRI.13. 
The Optic Neuritis treatment trial (ONTT) has  shown  female  
gender , one or more brain lesions on MRI, history of nonspecific 
neurological symptoms(usually transient  numbness) , prior optic neuritis 
in fellow eye or retrobulbar neuritis are positive risk factors for 
development of Multiple Sclerosis. 14   Similarly negative risk factors are 
male gender, no lesions on MRI, optic disc swelling, absence of pain and 
ophthalmoscopic findings of severe optic disc edema, peripapillary 
haemorrhages or retinal exudates. 
 
 
PATHOPHYSIOLOGY 
Inflammatory  demyelination  in central nervous system including 
optic nerves and visual pathway. It was previously thought as disease of 
myelin with sparing of nerve axons however neuronal and axonal loss are 
known to occur in MS, leading to permanent neurologic and visual 
impairment. 
 
 Activated peripheral T cells migrate across the blood brain barrier 
and release cytokines and other inflammatory mediators leading to 
neuronal cell death and axonal degeneration. After an acute event axons 
get damaged which leads to loss of axons which cause  severe and 
irreversible neurological impairment. 
 
Diagnostic criteria for MS was based on Poser clinical criteria    
1. Clinically definite MS  
2. Two attacks (relapses) of > 24 hours duration and more than one 
month apart together with clinical evidence of lesion in two places 
within the central nervous system. 
1. Laboratory supported definite MS includes evidence from lumbar 
puncture showing oligoclonal banding. 
 
 
2. Clinically propable MS above combination of clinical and 
paraclinical evidence but no oligoclonal bands. 
3. Laboratory supported propable MS oligoclonal banding without 
clinical or paraclinical evidence of lesions.15 
Retrobulbar neuritis and papillitis are mainly associated with MS. 
Perineuritis and neuroretinitis are most often associated with 
infectious or inflammatory pathologies. 16, 17,18, 19,13.  Neuroimaging (MRI) 
demonstrates white matter T2  signal abnormalities consistent with 
demyelination.20 
Optic neuritis can be typical or atypical.2,3,4,14,21  It is classified based 
on their clinical features and course of disease. 
 
NEUROMYELITIS OPTICA: 
It is variant of multiple sclerosis. Also known as  Devics  disease. 
It is an inflammatory or demyelinating disease of CNS. Patients can 
present with ON or transverse myelitis. Patients can present with 
unilateral or bilateral ON, transverse myelitis or both in close relationship 
to each other. 
 
 
 
Features of NMO are visual loss caused by damage to the anterior 
visual sensory pathways and paraplegia caused by damage to the spinal 
cord. Pain is not a definite feature. No definite pattern of visual field loss 
is noticed. Fundus shows a mild disc swelling associated with venous 
dilatation and extensive peripapillary exudation. Optic atrophy sets as a 
final sequela. CSF examination reveals lymphocytic pleocytosis. MRI 
shows abnormal T2 weighed signals and enhancement with gadolinium in 
the optic nerves, chiasm and spinal cord. 
 
INFECTIOUS/ PARAINFECTIOUS ON: 
Direct infection of the nerve (viral or bacterial) or inflammation 
triggered by an immune reaction to systemic or central nervous infection 
may cause an optic neuritis. Viruses such as adenovirus, Coxsackie virus, 
CMV, Hepatitis A virus, EBV, HIV and Measles, Mumps, Rubella and 
Varicella Zoster viruses. Bacterial infections resulting in the form of 
inflammation include syphilis, Lymes  disease , cat scratch disease. Optic 
neuritis usually occur within 1 to 3 weeks of the basic infection. This type 
of optic neuritis is more common in children. Optic disc may appear 
normal or may be swollen with associated peripapillary retinal edema. It 
may be associated with meningitis, encephalitis, or encephalomyelitis. 
 
 
CSF may show pleomorphic lymphocytosis and an elevated protein 
concentration. Visual recovery is excellent without treatment. 
Corticosteroids hastens recovery.2,3,4 
 
POST VACCINATION OPTIC NEURITIS : 
ON can occur after vaccination against both bacterial and viral 
infections. It may develop after vaccination with BCG, Hepatitis B virus, 
Rabies virus, Tetanus Toxoid, DPT and MMR. Influenza vaccine is most 
commonly associated with such presentation. Onset  usually within 1 to 3 
weeks. Most commonly bilateral. Visual recovery occurs few weeks to 
months.22,23,24  
 
  Optic neuritis in multiple sclerosis is characterised by subacute / 
acute unilateral visual loss which stabilizes by 1 to 2 weeks in patients 
between age of 20 to 50 years with clinical and neurological evidence of 
multiple sclerosis and no evidence of other disease process.2,3,4,21,9 .   
Features of typical optic neuritis: 
 Females are predominantly affected.   
 F:M ratio is 5:1.   
 
 
 Age 15 to 45 years 
 Unilateral 
 Acute and often painful loss of vision over hours to days. 
 Pain on eye movements. 
 Peak visual loss within 2 weeks. 
 Visual loss is subtle to complete which starts improving thereafter. 
 Relative afferent papillary defect often present. 
 Poor colour vision and contrast sensitivity. 
 Disc edema, vitreous cells, haemorrhages and cotton wool spots 
rarely present. 
 Fundus appears normal in retrobulbar neuritis. 
      Any type of visual field defect may be seen but generalised   
depression of visual field is the most common presentation. 
    
   VER (Visually evoked response) shows prolonged latency with 
normal or depressed amplitude. 
     
Patients may complain of residual deficits in contrast    sensitivity, 
colour vision, stereopsis, light brightness, visual  acuity or visual field. 
 Features of Atypical optic neuritis. 
 
 
 Age less than 20 or greater than 50 years 
 Painless loss of vision 
 Persistent pain lasting for more than 7 days. 
 Older patients are most commonly affected. 
 Bilateral presentation 
 Disc haemorrhages and cotton wool spots can occur. 
 Lack of significant improvement of visual function or worsening 
within the first three weeks after onset of symptoms. 
 Progression of visual field loss beyond 2 weeks. 
 Diagnosis or evidence of other systemic conditions  ( inflammatory 
or  infectious diseases including HIV infection) other than multiple 
sclerosis might cause optic neuropathy. 
 Patients fail to improve with treatment. 
  
 
 
CLINICAL ASSESMENT 
1. History 
2. Visual acuity 
3. Colour vision 
4. Pupil reflexes 
5. Biomicroscopy and Fundoscopy. 
6. Visual fields 
 
Associated symptoms might be movement phosphenes, sound induced 
phosphenes, visual obscuration of bright light and Uhthoff ‘s 
phenomenon. 
 
Other symptoms are less common. Loss of central vision is 
reported in 90% of patients.9   Loss of vision is usually abrupt occurring 
several hours to days. In some cases its minimally reduced,there is 
complete blindness with no perception of light. Not all the patients 
complain of loss of central vision. Some complain loss of peripheral 
vision such as superior or inferior region,such patients deny loss of 
central acuity and may found to have 20/20 or better in the affected eye.25  
Pain in and around the eye is present in 90% of patients. It is usually mild 
but it may be severe and extremely debilitating than loss of vision.  
 
 
 
1. Loss of vision 
Loss of central visual acuity is the major symptom in most cases of 
acute optic neuritis being reported by over 90% of patients.9 Loss of 
vision is abrupt occurring several hours to several days. The degree of 
visual loss varies widely. In some cases visual acuity is minimally 
reduced in others there is complete blindness with no perception of light. 
Visual loss is monocular in most cases, it can also be binocular. Best 
corrected visual acuity was measured with a wall mounted  Snellens 
Visual acuity chart at 6 metres distance. 
 
2. Loss of visual field 
Few patients complains of loss of central field of vision, some 
complain of loss of peripheral vision usually in a particular area of visual 
field such as superior or inferior region. Such patients deny loss of central 
acuity and may found to have 6/6 vision in the affected eye.25 
3. Ocular or orbital pain 
Pain in and around the eye is present in more than 90% of patients. 
It is usually mild but it may be extremely severe and more debilitating to 
the patient than loss of vision. It may precede or concurrently occur with 
vision loss. 
 
 
 
 In ONTT pain was reported by 92% of patients of whom 87% 
indicated that it was worsened by eye movement. Rose  theorized that the 
pain is caused by inflammation or swelling in the optic nerve sheath that 
are innervated by small branches of the trigeminal nerve.26  Lepore  
reported that among 101 eyes with optic neuritis, pain was more 
commonly present with retrobulbar neuritis than with papillitis.1  In 
ONTT pain was present in 93% of 295 eyes with retrobulbar neuritis and 
in 90% of 162 eyes with papillitis.  Majid et al reported painful eye 
movements in 12 patients in his study.51 
 
4. Positive visual phenomena 
Patients with optic neuritis experience positive visual phenomena 
called photopsia  in addition to pain and blurring both at onset of visual 
symptoms. Visual phenomena is precipitated by eye movements. Positive 
visual phenomena are reported by 30% of patients in the ONTT. 
 
 
 
 
 
 
 
OTHER SYMPTOMS: 
1) Movement phosphenes: 
It can occur before an attack of optic neuritis or may accompany 
visual loss during the attack or may occur 6 months after full recovery. It 
especially occurs in horizontal movements in dim lit room; very brief 
flashes of light lasting only for 1 or 2 seconds occurring unilaterally and 
in ipsilateral affected eye even when it is maintained in lateral gaze. It is 
due to demyelination and demyelinated nerve fibres may discharge 
spontaneously when subjected to minimal mechanical stress. 
 
2) Sound induced phosphenes: 
Phosphenes precipitated by sudden noise. 
 
3) Visual obscuration in bright light: 
It is due to fluctuating interference in the transmission of visual 
signals. 
 
 
 
 
 
 
 
 
 
 
 
4) Uhthoff’s symptom: 
It is an episodic transient obscuration of vision with exertion, hot 
baths, and showers. Patients have blurring of vision 5 to 20 minutes after 
exposure to provoking factor.  
 
SIGNS: 
1) Visual acuity: 
It can be variable from 6/9 to loss of  perception of light. In most of 
the cases visual acuity is reduced . Contrast sensitivity and colour vision 
is defective in most of the cases. 
 
The reduction in visual acuity parallels the reduction in contrast 
sensitivity.27   RAPD is present and detectable with a swinging flash light 
test. Patients with optic neuritis also can be shown to have a reduced 
sensation of brightness in the affected eye simply by asking them to 
compare the brightness of a light shined in one eye and then another or by 
performing more complex testing with a flickering light. 
 
 
 
 
2) Pupillary reflexes: 
RAPD is a office room test. It determines decreased vision in patient 
in optic nerve problems. 
 
Constriction of the ipsilateral pupil when the ipsilateral eye is 
stimulated by light, is called direct light reflex. Constriction of 
contralateral pupil when ipsilateral eye is stimulated by light, is called 
consensual light reflex.  
 
 
 
 
 
 
Light reflex pathway has two pathways 
1. Afferent pathway  extends from the retina along the optic nerve 
to the mid brain when a light is shone in that eye.(red) 
2. Efferent pathway  consist of parasympathetic fibres from mid 
brain back to both pupils via third cranial nerve and ciliary 
ganglion. It causes both pupils to constrict when light is 
stimulated. 
 
 
 
A swinging flash light test is used to detect RAPD.  It is the 
paradoxical response of a pupil to light.   
 
PROCEDURE:   
Patient is asked to fix at a distance.  A bright flash light is shone on 
to one eye from below or from temporal aspect and constriction of pupil 
is noted that eye. Then the flashlight is quickly moved to the contralateral 
eye and response of the pupil is noted. This swinging to and fro is 
repeated several times to look for the pupil response. Normally both the 
pupils constrict equally and the pupil to which light is transferred remains 
tightly constricted. In presence of RAPD in one eye, the affected pupil 
will dilate (paradoxical response) when the flash light is moved from the 
normal eye to the abnormal eye. This response is called Marcus Gunn 
pupil. 
 
 
 
Neutral density filters may be used to quantify the asymmetry in 
afferent input from each eye. It is used over normal eye while performing 
swinging flash light test. Filter placed in front of normal eye neurtralises 
the defect in abnormal eye. It is measured in log units.28 
 
 
 
 
3) Colour vision 
Colour vision is the ability of the eye to distinguish between colours 
excited by light of different wavelength. Dyschromatopsia  can be 
congenital or acquired.  Acquired loss of colour vision can be due to 
many causes. 88% of colour vision abnormalities was seen in optic 
neuritis. Mixed defects like red- green and blue- yellow were reported in 
ONTT trial.  Blue yellow defects were more common in acute phase of 
disease. Red-Green defects were more  seen at 6 months. 
 
Colour is purely a subjective sensation.29 It is mainly dependent on the 
wavelength composition of light entering the eye and on the structure of 
eye.31 
 
There are three theories of colour vision 
1. Opponent theory 
2. Trichromatic theory 
3. Zone theory 
 
 
 
 
 
COLOUR VISION TESTS: 
The main objective is to 31 
1. Screens the presence or absence of congenital or acquire colour 
deficiency 
2. Diagnose the type and severity of colour deficiency. 
3. Asses its significance in a particular vocation, employement or 
vocation. 
4. They are designed to perform various functions  
a) Screening test- identifies subjects with normal and abnormal 
colour vision. 
b) Grading test- estimates severity of colour vision 
c)  Vocational tests- identifies colour matching ability,hue 
discrimination and colour recognition. 
 
PSEUDOISOCHROMATIC PLATE 
1. Ishihara plates 
2. American Optical Hardy- Rand –Rittler Plates 
3. Standard Pseudoisochromatic Plates 
4. Colour Vision Testing Made Easy 
5. City University Test. 
 
 
Ishihara charts are based on the principle of confusion of the 
pigment colour in red –green colour defectives. It is easy and rapid test 
most commonly used for screening purposes. Charts are available in 
14,24 or 38 plates. 
 
INTERPRETATION: 
The plates are designed to be appreciated correctly in a room which 
is lit adequately by daylight. The plates are held at adistance75 cm 
perpendicular to the line of sight. Out of 21 plates, if 17 or more plates 
are read correctly by an individual his colour sense is regarded as normal. 
If 13 or less plates are read the the person has red- green colour defect.32 
 
 
 
 
 
 
American Optical Hardy- Rand –Ritter (HRR) is the test for choice 
for quantitative diagnosis. 
 
Standard Pseudoisochromatic Plates Part 2 for acquired colour 
deficiency.30,33 
 
It is an alternative method of colour vision assessment. It uses high 
resolution colour monitor. It is expensive. Designs are similar to Ishihara, 
HRR AND City university. 
 
 
 
 
City University Colour Assesment 
It is based on spatiotemporal luminance masking technique. In this, 
part of uniform background it is formed by spatially discrete elements 
that are equal in time averaged luminance with respect to the background, 
ensuring detection of the stimulus is based purely on chromatic 
discrimination and not luminance difference. This is designed to run on 
any monitor balanced approximately 9000K, which is the default factory 
setting for most colour monitors. 
 
GRADING COLOUR VISION DEFICIENCIES 
Spectral anomaloscope 
1. Nagel anomaloscope 
2.  Oculus HMC 
3.  Neitz anomaloscope 
4. Pickford – Nicolson anomaloscope. 
Anomaloscopes are used for screening, diagnosis, classification and 
grading of colour vision deficiencies. It is expensive and difficult to 
administer. 33,38 
 
 
 
 Arrangement tests ( Hue Discrimination Tests) 
1. Farnsworth Muller 100 Hue test 
2. Farnsworth Muller  dichotomous D 15 or Panel D 15 test 
3. Lanthony desaturated D 15  
4. Adams desturated D 15 test 
 
Farnsworth Muller 100 Hue test 
It is a very sensitive reliable and effective method of  determining 
colour vision defect. 
 
Farnsworth Muller  dichotomous D 15 
It is to distinguish observers with moderate or severe colour defects 
to those with milder defects.30 
 
Lantern test 
Its a colour naming test. Edridge –Green Lantern is designed to 
produce a range of colours and tints. It is an instrument used for testing 
the ability of a person to recognize colour of transmitted light. It was built 
to stimulate the light of railway signals as they are visible from distance. 
 
 
Test is performed in a dark room at six meters distance. Set of filters 
showing signal red, yellow, green and blue colours. 
 
Edridge –Green  Lantern 
 
Colour vision is almost affected in patients with optic neuritis. It is 
severely affected than visual acuity. Testing of colour vision is helpful in 
diagnosing ON in patients with minimal loss of vision. Contrast 
sensitivity measures the degree of detail perception in combination with 
perception of contrast.29   Ishihara pseudoisochromatic color plates can 
detect colour vision defects in eyes with retrobulbar neuritis and can 
detect evidence of optic nerve dysfunction. 
 
 
Marta Owidzka et al 60 reported in 27 patients of 33 eyes as 
contrast sensitivity is significantly reduced in all spatial frequencies both 
in photopic and mesopic conditions.  
 
Contrast sensitivity:  
It is the ability to perceive slight changes in luminance between 
regions which are not separated by definite borders. Ability to perceive 
sharp outlines of relatively small objects. Loss of contrast sensitivity is 
more important and disturbing to the patient than the loss of visual acuity. 
Even  in presence of normal visual acuity, contrast sensitivity can be 
impaired. 
 
Measurement of contrast sensitivity of human visual system was 
reported by Schade in form of Modulation transfer function.34 
 
Campbell and Green in 1968 first measured contrast sensitivity 
using sinusoidal gratings and concluded that measurement of contrast 
sensitivity gives more complete description of function of retina.35 
 
 
 
 
TYPES: 
1. Spatial contrast sensitivity 
2. Temporal contrast sensitivity 
Measurement: 
It is measured as (Lmax – Lmin) / (Lmax + Lmin). 
L  - Luminance recorded by photocells scanning across the 
gratings. 
3 variables in measurement of contrast sensitivity: 
1. Amount of light reflected depends on illumination of paper and 
darkness of ink. 
2. Degree of blackness in relation to the white background . i.e 
contrast 
3. The distance between the grating periods or cycles per degree of 
visual angle. 
Bodie Wollner introduced contrast sensitivity suggesting the 
name ‘visuogram’ to an ‘audiogram’ to describe a patients 
‘contrast sensitivity curve’. 
 
 
 
 
Deficits expressed in terms of decibels. Three types of deficits 
were described. 
1. High frequency type characterised by increasing loss at high 
frequency. 
2. A level loss type characterised by a similar loss for all spatial 
frequencies. 
3.  A selective loss type characterised by deficits in a narrow band 
of spatial frequencies. 
Methods to measure contrast sensitivity include simple plate 36, 
cathode ray tube display on a screen letter acuity charts.46   Visual field 
testing using low contrast rings on stimuli, pattern discrimination test, 
two alternative forced choice test. 
 
RELIABLE METHODS OF MEASURING CONTRAST 
SENSITIVITY 
1. Arden grating 
2. Cambridge low contrast gratings 
3. Pelli Robson contrast sensitivity chart 
 
 
 
 
Arden gratings: 
Arden in 197836  introduced a booklet containing seven plates – 
one screening plate(no 1) and six diagnostic plates (no 2 -7). The contrast 
changes from top to bottom and covers a range of approximately 1.76 log 
units. Plates are studied at 57 cm, with spatial frequency increasing from 
0.2 cycles /degree to 6.4 cycles/degree each being double the frequency . 
Cambridge  low contrast gratings: 
It consist of set of ten plates containing gratings in a spiral bound 
booklet. 
To perform this, booklet is hung on wall at a 6 metres distance. The 
pages are presented in pairs one above the other. One page in each pair 
contains gratings and the other is blank. Subject is require to choose 
which page top or bottom contains gratings. Pages are shown in 
descending contrast  
Pelli – Robson contrast sensitivity test: 
It consists of letters which subtends an angle of three degrees at a 
distance of one meter. The chart is printed on both the sides. The two 
sides have a different letter sequence. The letters on chart are organized 
as triplets, there being a two triplets in each line. The contrast decreases 
 
 
from one triplet to next. The log sensitivity varies from 0.00 -2.25. Chart 
is hung on the wall, it should be at the level of subjects eye. Chart is 
illuminated uniformly. Luminance of white area is between the 
accepatable range of 60 to 120 cd/m. It is recorded at 1 metre distance. 
Sensitivity is indicated by finest triplet for which two of the three letters 
are named correctly. 
 
 
RED DESATURATION: 
Most commonly used. It can be tested using bright coloured objects 
to compare the function of two eyes. Patient is asked to compare the 
saturation or redness of the object and indicate whether there is any less 
 
 
saturated redness in either eye indicating an acquired dyschromatopsia in 
that eye. Its a sign of optic nerve dysfunction. 
 
 
BRIGHTNESS COMPARISON: 
It can be subjective or objective. 
Subjective:  
 A bright beam of light is shone into the better eye and 
patient is asked to grade it as 100%. Then it is shone into the 
involved eye and the patient is asked to assign a percentage value 
to the brightness perceived in this eye as compared to normal eye. 
Eg 50% of the normal. 
 
 
Quantification: 
  It is done by putting a sequence of neutral density filters in 
the better eye and shining the light until the patient  states that the 
brightness is same in the both the eyes. 
 
In 89% of patients with optic neuritis poor brightness 
perception was reported .45,37. 
 
Visual fields: 
Visual pathway extends from retina to occipital cortex. It is 
an extra cerebral course. Damage to the nerve fibres along the  
visual pathway cause variety of field defects. Complex course of 
nerve fibres within the visual pathway and any damage to the fibres 
at certain location will produce visual field defects. 
 
 
 
FIGURE :  1.1 Lesions along the optic pathways showing visual field 
defects. 
Testing of central and peripheral visual fields is important: 
1. To detect abnormality in vision. 
2. To localize the defect along the afferent visual pathway. 
3. To quantitate the defect and measure the change over time. 
Visual field testing can be divided into static and kinetic which can 
be manual or automated. Automated perimetry lacks field defects shape 
details, but it is proved to be more sensitive than kinetic testing.  
 
 
 
The following are the methods in visual field testing 
a) Confrontation methods 
b) Amsler  grid 
c) Tangent screen 
d) Goldmann perimetry. 
Confrontation methods: 
This is a rapid screening method where examiner compares 
patients field with their own. 
Finger counting: 
Patients are instructed to accurately identify the number of fingers 
presented in each quadrant of the monocular field. 
Simultaneous finger counting may bring out a subtle defect.  
Test :  
Patient covers one eye with the palm of one hand and look at the 
examiners nose a feet away. The examiner closes his eyes opposite from 
the patients covered eye and have the patient fixate on the examiners 
open eye. 
 
 
The patient while fixating should be asked whether he can see the 
examiners eyes, ears, hair, mouth etc which would reveal a large 
scotoma. 
Hand comparison : 
Simultaneous perception of hands placed on either side of vertical 
meridian providing a sensitive subjective comparison of the two 
hemifields. 
Hands placed in the superior and inferior fields to determine 
whether there is an altitudinal defect. 
Colour comparison : 
Done in similar way with the patient occluding one eye. The 
examiner holds a red coloured object in each hand and asks whether the 
red objects appear the same in each hand. In a relative scotoma one object 
might appear less red than the other. 
A central scotoma of the field  can be detected by asking the 
patient to describe changes in the saturation of the colour of a large object 
moved away or toward central fixation. 
 
 
 
b)  Amsler grid : 
Screens central 10 degree of fixation. Patient optically corrected 
for near vision covers one eye and looks at fixation point in the centre of 
a grid. Patient is then asked to describe any scotoma. 
 
c) Tangent screen: 
        It is a valuable sensitive method of evaluating  or   screening visual 
field defects. It offers relative magnification of the surface area at 1 or 2 
m (when compared to other perimeters  at5 33 cm).  It allows detailed 
exploration of small central scotomas. Tangent screen is less quantitative 
and standardized. 
 
 
 
Method: 
The patient gazes with one eye at black screen with the other eye 
occluded 1- 2 metres away in good lighting and fixes on a central spot. 
Thin black wand with various targets on tip is used by the examiner. 
Initially a suprathreshold stimulus is used such as 5mm white target at 
1m. stimulus is moved from non seeing area to seeing area. 
The target is a flat disc white or red on one side, black on reverse 
so that it can be flipped over with course of the test so that black surface 
is not seen by the patients it blends with the screen. Patients are instructed 
to indicate verbally or by gesture when they first see the target only, not 
the wand or examiners hand. 
Blind spot can be detected using larger stimulus.  Central fields( 
fixation area) explores scotoma in the central region of fixation and the 
area between blind spot. 
d) Goldmann perimetry: 
It is useful for evaluating both central and peripheral fields. The 
perimetry can be used along with a moving target ( kinetic) or stationary 
target (static perimetry). It is standardized and reproducible target and 
background luminance (i.e contrast). Humphrey Visual Field Analyser   
 
 
(HVFA) sensitivity mainly requires patient’s co-operation and 
competence, good technician to monitor the patient. 
In ONTT, patients underwent HVF testing.  Perimetry revealed that 
48% present with a diffuse field defect ( Figure 1.2), 20% with altitudinal 
or arcuate defects and 8% present with a centrocaecal defect 44. . Initially 
it was found that centrocaecal scotoma was common defect in optic 
neuritis. However it is now believed that the central scotoma found by 
Goldmann perimetry represents diffuse suppression of sensitivity within 
the central 30 degrees of vision.43  Central visual loss is common in optic 
neuritis patients  and sparing of the periphery, it is rare for the peripheral 
field to be abnormal in the presence of a normal central field. 
 
    
Figure 1.2: Humphrey visual field analysis  showing diffuse loss of 
sensitivity with a dense central scotoma in optic neuritis. 
 
 
Other test are 
1) Stereoacuity : 
The Titmus Polaroid 3D Vectograph stereoacuity is recommended 
for both children and adults with optic neuritis. 
The Pulfrich effect in which patient experience a stereoillusion by 
having the patient gaze at a pendulum swinging at right angles to the line 
of sight and determining if the pendulum appears to the patient to be 
swinging in an elliptical path is a sensitive indicator. 
 
2) Visual Evoked Potential: 
It a specific change in Electroencephalographic (EEG) recording 
due to stimulation of the visual pathway to either a pattern or flash 
stimulus. Recordings of evoked potentials can be made with the use of 
electrodes applied to the scalp.  The main signals are detected over the 
occipital cortex. The VEP signal is mainly derived from the  macular 
region as the predominant function of the occipital cortex is to subserve 
macular function. 
It differentiates organic from functional cause of defective vision. 
It tests central and perifoveal visual field and there is prolongation of P 
latency which is a permanent change. The P100 amplitude is correlated 
 
 
with visual acuity and P latency is also an indicator of optic nerve 
dysfunction. In pattern shift VEP it provides evidence of optic nerve 
pathology in optic neuritis. 
3)Pattern electroretinogram( PERG) 
 It monitors integrity of central ganglion cell layer. It is of value in 
improved  interpretation of abnormal VEP pattern when both are recorded 
simultaneously  to rule out if delay in pattern VEP P latency in a patient 
with suspected optic nerve demyelination. 
 
4)Pupillary light reflex latency: 
Prolonged latency of papillary light reflex which is measured using 
infrared reflection. 
5)Foveal critical flicker frequency is impaired 
Subjective brightness measured by Authorn Flicker test in relation 
to flicker frequency is abnormal. 
OPTIC DISC FINDINGS: 
 Normal in retrobulbar neuritis 
 Swollen disc in papillitis. 
 Marshal et al reported Central or paracentral scotoma with or without 
peripheral extension represents 90% of field defects. 
 
 
MAGNETIC RESONANCE IMAGING: 
PRINCIPLE: 
MRI works on basis of hydrogen atom which is the important atom 
present in the body.  MRI imaging is mainly based on the movement of 
hydrogen protons in magnetic field. Protons are stimulated by the 
radiofrequency coil and then left to relax in the direction of magnetic 
field creating energy that is used for development of images. 
 
 
 
 
MRI shows the size ,quantity and distribution of lesions larger than 
2mm, and together with supporting evidence helps in the diagnosis of 
MS. 
Magnetic Resonance Imaging is helpful in diagnosis of clinically 
silent multiple sclerosis lesions. 
 
MRI criteria for diagnosing MS 
At least 3 lesions and two of the following should be present for 
the diagnosis of MS to be present;39 
1. 1.Lesions in the lateral ventricles 
2. Lesions with diameters greater than 5mm 
3. Lesions present in posterior fossa (infratentorial). 
 
MRI features in optic neuritis: 
MRI shows typical periventricular and corpus callosum plaques in 
multiple sclerosis. The plaques typically have an ovoid shape with their 
long axis perpendicular to the ventricular margins. Acute demyelinating 
lesions may be highlighted with gadolinium on T1 weighted scans. 
 
 
 40 – 70 % of patients are reported to have periventricular white 
matter changes on MRI consistent with MS in cases of  isolated optic 
neuritis. In ONTT, MRI  scans were the strong predictor of developing 
MS performed at study entry. 10 year risk of MS ranging from 22% in 
patients with no MRI lesions, 56% in patients with one or more lesions.41 
 
    
 
Optical Coherence Tomography:  
It is a non invasive measurement  using  infrared light to reflect 
retinal thickness which is associated with axonal and neuronal 
degeneration. 40,42. 
 
 
SYSTEMIC INVESTIGATIONS 
1. Routine hemogram 
2.  X-ray (Chest) 
3. Mantoux 
4. FTA - ABS & VDRL for syphilis 
5. serology and culture for bartonella 
6.  Markers of viral infection 
7. Serum electrolytes and fasting blood sugar 
8. MRI 
9. Lumbar puncture and CSF tap (IgG index and oligoclonal bands) 
10. Blood culture 
11. ANA, dsDNA 
12. Serology for toxoplasmosis 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
DIFFERENTIAL DIAGNOSIS 
1. Ischemic optic neuropathy, it is characterized by lack of pain, pallid 
disc swelling with haemorrhages. Altitudinal visual field defect. Lack 
of improvement of vision with standard therapy. 
2.   Lebers optic neuropathy it is characterized by lack of pain, 
circumpapillary telengiactatic microangiopathy 
3. AION 
4. Toxic or nutritional deficiency amblyopia 
5. Non organic visual loss 
6. Other  
a. posterior uveitis 
b. CSCR 
c. Disc drusen 
d. Glaucoma 
e. Posterior scleritis 
 
MANAGEMENT 
Corticosteroids are main stay of treatment. It can be oral,   
parenteral or retrobulbar route. 
 
 
 
 
PREDNISOLONE: 
It is a adrenocortical steroid which are naturally occurring and 
synthetic,readily absorbed from the gastrointestinal tract. It is a white 
crystalline powder very slightly soluble in water. It is designated 
chemically as pregna-1,4-diene-3,20-dione,11,17,21-trihydroxy-(11 β).  
The structural formula is represented below: 
 
 
 
Mechanism of action: 
It suppress inflammatory and immune response and alter leucocyte 
function. 
 
 
METHYLPREDNISOLONE: 
It is steroid that prevents the release of substances in the body that 
cause inflammation. 
 
COMPLICATIONS OF STEROIDS: 
OCULAR: 
Eyelids: 
a) allergic reactions 
b) telengiectasia 
c) persistent erythema 
 
Cornea: 
a) Superficial punctuate keratitis 
b) Delayed healing of corneal wounds 
 
GENERAL 
1. Increased IOP 
2. Delayed healing of corneal wounds. 
3. Mydriasis – precipitate angle closure glaucoma 
 
 
4. complicated cataract 
5. Enhances lytic action of collagenase 
SYSTEMIC COMPLICATIONS: 
A) Dermatological : 
1) Acne 
2) Hirsuitism 
3) Subcutaneous tissue atrophy 
 
B)    Immunological: 
1) Impaired inflammatory response 
2) Delayed tissue healing 
 
C) Metabolic: 
1) Secondary diabetis mellitus 
2) Hyperosmotic ketoacidosis 
3) Centripetal obesity 
4) Hyperlipidemia 
 
    D) Cardiovascular: 
1) hypertension 
2) sodim and fluid retention 
 
 
E) Musculoskeletal: 
1) osteoporosis 
2) vertebral compression fracture 
 
F) Gastrointestinal: 
1) peptic ulcer 
2) gastric haemorrhage 
3) intestinal perforation 
4) pancreatitis 
 
G) Endocrine: 
1) Adrenal insufficiency 
2) Cushing s syndrome 
3) Growth failure 
4) Menstrual disorders 
H) Neuro Psychiatric: 
1) Pseudotumour cerebi 
2) insomnia 
3) mood swings 
4) psychosis 
 
 
OPTIC NEURITIS TREATMENT TRIAL: 
ONTT is a multicentered randomized trial involving 454 patients 
from 1988 to 2006. This study evaluated the efficacy of corticosteroid 
treatment for acute optic neuritis. 
Study objective: 
It  evaluates the efficacy of corticosteroid treatment  in acute optic 
neuritis relationship between optic neuritis and multiple sclerosis. 
The patients in this study were randomized into 3 different groups 
1. IV methyl prednisolone(250 mg 6 hrly ) for three days followed by 
oral prednisolone for 11 days and three day tapering of 
prednisolone. 
2. Oral prednisolone (1mg/kg/day) for 14 days followed by 3 days in 
tapering doses. 
3. Oral placebo for 14 days. 
Results: 
Intravenous methyl prednisolone 1gram  followed by Oral 
Prednisolone  1mg/kg  speeds the recovery of visual loss due to optic 
neuritis and results in a slightly better vision at six months. 
 
 
STUDIES INVOLVED IN OPTIC NEURITIS TREATMENT: 
CHAMPS STUDY (The Controlled High Risk Avonex Multiple 
Sclerosis Trial) 
Objective : 
Avonex   (interferon beta 1 a) treatment would benefit patients who 
had experienced a demyelinating event involving the optic nerve, brain 
stem/cerebellum or spinal cord.  Previously,brain abnormalities  in MRI 
predicted  likelihood of future MS like events. All patients received  
intravenous methylprednisolone 1g per day for three days within the days 
of onset of neurological symptoms, followed by oral prednisolone with 
tapering dose of 1mg/kg for 11 days. Patients were divided into two 
groups  
Group 1 once weekly intramuscular injection of interferon beta 1 A 
Group 2 placebo injections 
Outcome was measured by development of CDMS and change in 
demyelinating lesions on serial brain MRI scans. 
 
 
 
 
Results  
At three years end,the probability of CDMS was 50% in the 
placebo treated group and 35% in the interferon 1 A treated group. There 
was no difference among treatment options among patients presenting 
with optic neuritis, brain stem/cerebellar or spinal cord events. Treatment 
with Avonex significantly reduces the two year likelihood of future 
neurological events and worsening of brain MRI in patients with a first 
acute CNS demyelinating event. 
ETOMS (Early Treatment Of Multiple Sclerosis Study) 
Objective: 
To determine whether an early treatment with interferonb  1 b is 
effective in delaying the development of CDMS after the first attack. 
Study entered 308 first attack patients, ages 18-40 years with 
unifocal or multifocal (39%) CNS presentations and abnormal brain MRI.  
Patients were assigned to receive IFN beta 1 A 22mcg SC weekly or 
placebo. These patients were followed for 2 years. 
 
 
 
 
CHAMPIONS STUDY (Controlled High Risk Avonex Multiple sclerosis 
Prevention Surveillance) 
Objective: 
Outcomes are compared in those who had given drug from the start 
of CHAMPS study (immediate treatment) versus those who had switched 
from placebo after about 30 months. (delayed treatment). 
Results: 
Immediate group had few relapses and fewer MRI lesions than the 
delayed group and few of its members converted to definite MS. 
BENEFIT STUDY: (Betaferon in Newly Emerging MS for Initial 
Treatment) 
Beta interferon 1b double blind , placebo controlled trial in patients 
with first episode suggestive of MS. Results showed risk of developing 
MS within a year was reduced by 46% . 
 
 
 
 
 
 
Newer modalities: 
It can modify the disease course 
1. Copolymer 1 
2. T cell receptor peptide immunisation 
3. Anti CD 4 monoclonal antibody 
4. Azathioprine ( Imuran) 
5. Cyclophosphamide (cytoxan) 
6. Oral myelin 
7. Methotrexate 
8. Cladribine 
9. Intravenous immunoglobulin G 
 
 
 
 
  
 
 
AIM AND OBJECTIVES 
To study the visual function, response to treatment and visual 
outcome in patients with optic neuritis presenting to the 
Neuroophthalmology clinic at Aravind Eye Hospital, Madurai, South 
India. 
  
 
 
MATERIALS AND METHODS 
 Prospective observational case study. 
 To analyse visual function, response to treatment and visual outcome 
in patients with optic neuritis. 
 Study period:  January 2013 to December 2013. 
 Study duration: 13 months (including followup) 
 Data source:  Hospital records. (Aravind Eye Hospital) 
 Sample size:  88 patients /98 eyes. 
 Follow up period of 2 weeks, 1 month. 
 
INCLUSION  CRITERIA:  
 Age  16 -65 years   
 Loss of visual acuity or visual field, with or without pain < 1month 
duration. 
 Unilateral / bilateral  
 Fundus changes 
 Field defects  
 
 
 
 
EXCLUSION CRITERIA 
 Age < 16 years 
 Visual loss including toxic, metabolic, vascular, hereditary, 
compressive neuropathies. 
 Previous episode of optic neuritis in the affected eye. 
 Informed consent was obtained from all patients. 
  
 
 
CLINICAL EVALUATION: 
  A series of 98 eyes of 88 patients who presented to our  
Neuroophthalmology  department were included in our study. 
Optic neuritis was diagnosed  based on history and clinical 
examination which included  defective vision , dychromatopsia, pain on 
eye movements, presence of Relative Afferent papillary defect, normal or 
swollen optic disc on fundus examination of less than 1 month duration 
were included in our study. All these patients underwent a thorough 
ophthalmological  and neurological evaluation. 
Patient ‘s data such as name, age , sex, address were documented in  
a proforma. 
Detailed history of  each and every symptom like onset, duration, 
pain on eye movement , headache  were documented.  Patients were also 
enquired  about   history of prior  visual loss. 
Each one of the patient included in our study have to undergo 
 Visual acuity by means of Snellens’s chart 
 Refraction 
 Pupillary reaction to look for RAPD, sluggish pupil 
 General ophthalmic examination by torch light and slit lamp. 
 
 
 Intraocular pressure measurement for patients above 40 years of 
age by Non contact  tonometry  method. 
 Fundus examination by direct ophthalmoscope and slitlamp 
biomicroscopy  using +90 dioptre lens. 
 Colour vision was assessed in detail by Ishihara’s colour vision 
chart, red desaturation, brightness sensitivity. 
 Central fields tested by Bjerrums’s  tangent screen. 
 Neuroimaging was done depending upon the need and affordability 
of the individual patients. 
 Basic blood investigations like random blood sugar, total leucocyte  
count, differential leucocyte count and erythrocyte sedimentation 
rate was done for all patients. 
 All patients in our study received 1 gram of intravenous methyl 
prednisolne for 3 days followed by oral prednisolone of 
1mg/kg/body weight for 2- 4 weeks. 
 Improvement in Patient’s visual acuity, colour vision, brightness 
sensitivity, red desaturation ,  visual fields and fundus were 
assessed during follow up examinations at 15 days and 1 month. 
 
 
 
 
ANALYSIS 
Analysis of collected data was done based on the following 
1. Incidence 
2. Age and sex distribution 
3. Onset of symptoms 
4. Presenting visual acuity 
5. No PL/ PL / HM /1/60 
6. 1/60 – 6/60 
7. 6/60 – 6/6 
8. Pupil -  normal  / RAPD. 
9. Colour vision - Normal / defective / inconclusive because 
of poor vision. 
10. Central fields 
11. Fundus status – normal / abnormal. 
12. Visual acuity, colour vision ,  red desaturation,  
brightness sensitivity, central fields at follow up. 
13. Fundus status at follow up. 
  
 
 
STATISTICAL METHODS 
Mean (SD) or Frequency (percentage) was used to describe 
summary data.  Wilcoxon signed rank sum test was used to assess the 
difference between paired data.  McNemar’s test was used to assess the 
difference between pre-post binary data.  P-value is less than 0.05 
considered as statistically significant.  All statistical analysis was done by 
statistical software STATA 11.1 (Texas, USA). 
 
 
  
 
 
RESULTS 
Study included 98 eyes of 88 patients with optic neuritis. Visual 
function parameters showed rapid recovery following treatment with 
steroids compared to pretreatment levels in our patients. 
TABLE 1.  INCIDENCE 
Cases n 
Incidence of Optic 
Neuritis 
Total number of  Neuro 
ophthalmology cases during the 
study period 
5,394 
16.3 patients per 
1000 
 
Total number of new cases with 
optic neuritis 
88 
 
 
 
 
 
 
The mean age is 40.0 (12.9) years and the range is 20 to 64 years.
Majority of patients in the s
years. (52.3%) 
 
 
 
 
41 - 60 
40%
 
TABLE 2: AGE 
tudy belonged to the age group 2
20 - 40 
52%
>60
8%
Age category
20 - 40 41 - 60 >60
 
 
0- 40 
Out of 88 patients 47 were males (53.4%) and 41 were females 
(46.6%) 
 
 
 
 
 
 
Female
47%
 
TABLE 3: GENDER 
Sex
 
Male
53%
TABLE 4: 
Out of 88 patients, 78 (79.6%) of them showed unilateral 
involvement and 10 (20.4%) showed bilateral involvement.
Bilateral
20%
 
LATERALITY 
 
 
 
 
 
 
Unilateral
80%
Laterality
 
 
 
TABLE 5: COMPLAINTS 
 
 
Defective vision was presented in 90 eyes (91.8%) followed by 
dyschromatopsia in 20 eyes(20.4%). Pain on eye movements was 
presented in 29 eyes (29.6%). Headache was presented in 11 patients 
(12.5%). 
 
 
92
30
12.5
20
0
10
20
30
40
50
60
70
80
90
100
Defective vision Pain on eye 
movements
Headache Defective colour 
vision
P
e
rc
e
n
ta
ge
Complaints
 
 
TABLE 6:VISUAL ACUITY 
Visual acuity Baseline 1month 
6/6 – 6/18  19(19.4) 45(58.4) 
6/24 – 6/60  13(13.3) 15(19.5) 
6/60 – 3/60 36(36.7) 11(14.3) 
<3/60 30(30.6) 6(7.8) 
Total 98 77 
 
At baseline 32.7% of patients had V/A  >6/60. 67.3% patients had 
V/A  <6/60. About 78 % of patients had 6/60 or better vision  at 1 month 
follow up. 
 
19.3
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13.3
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14.3
30.6
7.8
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Visual acuity
6/6 - 6/18 6/24 - 6/0 5/60 - 3/60 <3/60
 
 
Log mar 
vision 
N 
Median 
(Snellen’SEquivalent) 
Mean(SD) 
Min-
Max 
P-Value 
Baseline 98 1.48(2/60) 1.54(0.94) 0 – 3.2 - 
2 weeks 92 0.39(6/15) 0.74(0.84) 0 – 2.9 <0.001 
1 month 77 0.3(6/12) 0.67(0.83) 0 – 2.9 <0.001 
 
Improvement in visual acuity was statistically significant at 1 
month (p = <0.001) compared to the baseline. 
Baseline median LogMAR visual acuity was 1.48 which improved 
to 0.3 after 1 month. 
PUPIL 
Pupil N % 
Normal 12 12.2 
RAPD 86 87.8 
Total 98 100.0 
 
 At baseline 12.2% showed normal pupillary reaction. 87.8% 
showed RAPD. 
 
At baseline, in 15 eyes optic disc was normal, 44 eyes showed disc 
edema, 20 eyes showed temporal pallor, hypere
month, out of 77 eyes 19 
pallor, 12  eyes showed hyperemia, 16 eyes showed resolving disc edema, 
3 eyes showed  primary optic atrophy
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TABLE 7: FUNDUS 
mia in 20 eyes.  At 1 
eyes was normal, 28 eyes showed temporal 
 
Temporal 
pallor
Hyperemia Resolving 
disc edema
Optic 
atrophy
19 20
27
11
16
Fundus
Baseline 1 Month
 
3
 
 
Fundus at 
baseline 
Fundus at 1month 
Total P-value 
Normal Abnormal 
Normal 9(69.2) 4(30.8) 13 0.180 
(Using 
McNemar’s test) 
Abnormal 10(15.6) 54(84.4) 64 
Total 19 58 77 
 
At baseline, 98 eyes were assessed and 15 eyes (15.3%) were 
normal and others were abnormal. At 1 month follow up of 77 eyes 
(remaining 21 were lost to follow-up), 19 eyes (24.7%) were only normal 
and others were abnormal. 15.6% (10) out of 64 patients  were normal at 
final visit which were abnormal at baseline visit. At 1 month follow up, 
fundus did not show statistically significant improvement compared to 
baseline (P value = 0.180, Using  McNemar’s test).   
 
 
 
 
 
 
TABLE 8:
 
 
Colour vision at 
baseline 
Colour vision at 
Normal
Normal 7(87.5)
Dyschromatopsia  46(66.7)
Total 53(68.8)
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DYSCHROMATOPSIA 
1month Total P-value
 Abnormal 
 1(12.5) 8 0.0035
(Using 
McNemar’s 
test)
 23(33.3) 69 
 24(31.2) 77 
1 month
68.8%
87.8%
31.2%
Dyschromatopsia
Normal Defective
 
 
 
 
 
At baseline 12.2% (12) were normal 87.8% (86) were abnormal. At 
follow up of 1 month of 77 eyes
were abnormal . 46 eyes (66.7%) were normal at 1month follow
which was abnormal in baseline.  Colour vision at 1month 
statistically showed  significant improvement. (P
McNemar’s test) 
TABLE :
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  68.8% (53) were normal and 31.2% (24) 
follow
-value=0.004, Using  
 9 CENTRAL FIELDS 
Central Fields
-up 
-up  
 
Baseline
1 month
 
 
Central fields 
at baseline 
Central fields at 
1month Total P-value 
Normal Abnormal 
Normal 7(100.0) - 7 <0.001 
(Using 
McNemar’s test) 
Abnormal 29(41.4) 41(58.6) 70 
Total 36(46.8) 41(53.2) 77 
 
At baseline 12.2% (12) were normal and at 1month 45.3% (34) 
were normal. 29(41.4%) eyes were normal at 1month follow-up who 
were abnormal at baseline.  Central fields  statistically showed significant 
improvement at 1month follow-up visit (P-value <0.001, Using 
McNemar’s test) 
 
 
 
 
 
 
TABLE 10: BRIGHTNESS SENSITIVITY
 
Brightness 
at baseline 
Brightness at 1month
Normal
Normal 8(80.0)
Reduced 35(52.2)
Total 43(55.8)
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Total P-value
 Abnormal 
 2(20.0) 10 0.0001
(Using 
McNemar’s test)
 
 32(47.8) 67 
 34(44.2) 77 
1 month
55.8%
84.7%
44.2%
Normal Reduced
 
 
 
 
 
 
At baseline, 15.3% (15) were normal 84.7% (83) were abnormal. 
At follow up of 1 month out of 67 eyes 43(55.8%) eyes showed 
improvement.  35(52.2%) eyes were normal at 1month follow-up who 
were abnormal at baseline.  Brightness sensitivity  statistically showed 
significant improvement at 1month (P-value=0.0001, UsingMcNemar’s 
test). 
  
TABLE 
 
Red 
Desaturation 
at baseline 
Red D
Normal
Normal 6(75.0)
Reduced 37(53.6)
Total 43
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11: RED DESATURATION 
esaturation at 
1month Total P-value
 Abnormal 
 2(25.0) 8 
0.0001
(Using 
McNemar’s test)
 32(46.4) 69 
 34 77 
1 month
55.8%
87.8%
44.2%
Red desaturation
Normal Reduced
 
 
 
 
 
 
 
At baseline, 12(12.2%) eyes were normal. At follow up of 1 month, 
43 (55.8%) eyes showed improvement.  37(53.6%) were normal at 
1month follow-up who were abnormal at baseline.  Redsaturation  
statistically showed significant improvement at 1month follow-up (P-
value=0.0001, Using McNemar’s test). 
Neuroimaging 
Neuroimaging  was not possible in all cases due to financial 
constraints. It was performed in 35 cases. MRI was done in 23 cases and 
CT was done in 12 cases. No lesions was seen in 7 cases, 25 had shown 
thickening and enhancement of optic nerve in the affected eye. 
Demyelinating lesions in the brain were present in 3 cases. 
 
                                                    
 
 
 
 
 
 
 
 
 
 
DISCUSSION 
Optic neuritis is inflammation of optic nerve which is mostly 
idiopathic in nature. 
 
In natural course of optic neuritis spontaneous recovery occurs 
within 1 week  but it may take longer time in few cases. Typical cases of 
optic neuritis  due to multiple sclerosis was not commonly seen in India 
 
  Many studies have been conducted which reports the association 
of optic neuritis with multiple sclerosis. Before ONTT, Jain et al 50 
reported that clinical profile of optic neuritis in India is different from that 
of Western population.  The aim of our study is to understand visual 
function following optic neuritis treatment in South India. 
 
The role of corticosteroids in the management of optic neuritis was 
initially undertaken by Optic neuritis Treatment Trial which shaped our 
understanding of optic neuritis. All patients in our study received 
Intravenous methyl prednisolone  1 gram once daily for 3 days  followed 
by oral steroids (1mg/kg body weight)  for 2 – 6 weeks with tapering 
doses. 
 
 
88 patients aged between 20 to 64 years (mean age 40.0 ) were 
enrolled in the study out of which 47  were male and 41 female.78 
patients showed unilateral involvement, 10 patients showed bilateral 
involvement.  A similar study was conducted by Rohit Saxena et al 48 
included  83 patients  between the age of 15 – 58 years ( mean age 27.6 
years) of which 67 cases had unilateral involvement and 16 cases  had 
bilateral involvement. ONTT included 457 patients with ages ranging 
from 18 – 46 years (mean age 31.8 years) 49. 
 
Males were commonly affected in our study (53.4%) compared to 
females. A similar study conducted by Jain et al50 showed 67% of male 
involvement in their study.  In ONTT, 77% of patients affected were 
females.49 
 
Most common presentation in our study was defective vision 
present in 91.8% (90 out of 98 eyes) , headache in 12.5% (11 out of 98 
eyes), dyschromatopsia in  20.4% (20 out of 98 eyes) pain on eye 
movements present in 29.6% (29 out of 98 eyes). Similarly Jain et al50 
found 33.3% (7 out of 42 patients) had  pain on eye movements in their 
study. In ONTT pain was present in 93% of 295 eyes with retrobulbar 
 
 
neuritis and in 90% of 162 eyes with papillitis.  Majid et al51 reported 
painful eye movements in 12 patients in their study. 
 
In most of the eyes visual acuity was worse at baseline. At follow 
up of 1 month  in 15 (19.5%) eyes visual acuity was 6/24 or better.  In 
45(58.4%) eyes visual acuity was 6/18- 6/6. Similarly Pedro et al reported 
improvement of visual acuity of 52.4% in 18 eyes out 35 eyes at follow 
up.56 
 
Out of 98 eyes 86 (87.8%) eyes showed RAPD. 12 (12.2%) eyes 
were normal at baseline.  
 
At baseline, in 15 eyes optic disc was normal, 44 eyes showed disc 
edema, 20 eyes showed temporal pallor, hyperemia in 20 eyes. Other 
findings were splinter haemorrhages seen in 2 eyes.  ONTT reported  
swollen optic disc  was seen in 35%. Nikoskelainen et al reported  optic 
disc was normal in 46%, hyperemic/ blurred disc in 20%, disc edema in 
23% and 11% showing temporal pallor. 
 
 
Papillitis was seen in 65.3% and retrobulbar neuritis in 34.7 % of 
patients in our study. Similarly Saxena48 et al reported 53.5% of eyes had 
papillitis and retrobulbar neuritis was seen in 46.5%. 
 
Visual fields at baseline were done only in 48 eyes, it could not be 
performed in 50 eyes because of poor vision. Most common field defect 
was centrocaecal  scotoma seen in 22 (22.7) eyes.  7.8% in our study had 
superior and inferior field defect generalised constriction of visual field 
and superior field loss.  In our study 1 patient had altitudinal field defect 
at baseline which is common in NAION can also present in ON.  
Similarly ONTT54 reported  48.2% showed diffuse loss , 8.3% central or 
centrocaecal scotoma and  altitudinal field defects in 23.4% eyes which 
was the most common field defects at baseline.  Jain et al reported 
concentric contraction was seen in 25% of eyes followed by central 
scotoma seen in 19.1% eyes. 
 
Dyschromatopsia  was recorded using Ishihara charts.  At baseline 
86 (87.8%)eyes  it was abnormal 12( 12.2%) eyes it was normal. At 1 
month 53(68.8%) eyes showed improvement. 24(31.2%) did not show 
improvement. Jain et al reported recovery of dyschromatopsia along with 
recovery of vision in their study.  Saxena et al48 reported 60.6% showed 
 
 
improvement in colour vision in their study. Vimala et al reported 
improvement of dyschromatopsia  at 1 month follow up. (Mean Log mar 
at baseline was 9.14 which improved to 18.57)59 
 
Brightness sensitivity - Out 98 eyes 83 were abnormal at baseline, 
in most it could not be performed due to poor vision. At follow up of 1 
month 43(55.8%) eyes out of 77 eyes showed improvement. Brightness 
testing appeared to be more sensitive than other techniques in establishing 
the diagnosis.37. 
 
Red desaturation – Out of 98 eyes 86 eyes were abnormal at 
baseline. At follow up of 1 month ,out of 77 eyes 43 eyes showed 
improvement. In our study we have included brightness sensitivity and 
Red Desaturation as one of the important parameters for evaluation of 
visual function. Similarly Almong et al has shown increased desaturation 
in ON in their study.55 
 
Neuro imaging  showed demyelinating lesion in the brain which 
was present only in 3 cases in our study showing that incidence of MS is 
low in South India. ONTT54 reported that demyelinating changes 
 
 
consistent with MS were seen in 37.5% (8 cases out of 32) and with 
contrast, it was 48.7%     (203 cases out of 417).  It also reported that risk 
of developing MS after an attack of optic neuritis was 50% and if the 
baseline MRI is negative the risk of MS was 25%.  Saxena et al48 reported 
12 cases showed demyelinating lesion and 4 cases showed MS in their 
study.  Jain et al reported that incidence of MS is low in southern part of 
India compared to northern India. 
 
 
 
 
 
 
 
 
 
 
 
 
LIMITATIONS 
1. The follow up period was very short to evaluate the long term 
prognosis. 
2. Favourable visual outcome of ON prohibited patients from 
returning to our department for long term follow up. 
3. MRI was done only in 35 patients due to financial constraints. 
4. HFA was not done in all the patients due to financial constraints. 
 
 
 
  
 
 
                                    CONCLUSION 
 
1. The age range is 20 to 64 years with mean age 40.0(12.9) years. 
 
2. 79.6 % of patients had unilateral presentation. 
 
3. 20.4% patients had bilateral presentation.  
 
4. There is a slight male preponderance in our study. 
 
5. Defective vision followed by pain on eye movements are the chief 
complaints in our study. 
 
6. There was a significant improvement in visual acuity. 
 
7. The most common presentation was papillitis (65.3%) followed by 
retrobulbar neuritis (34.7%) 
 
8. Visual function like central fields, colour vision, Brightness 
sensitivity, Red desaturation showed a significant improvement 
following treatment. 
 
9. Neuro imaging showed signs of demyelination  in 3 patients. 
 
 
 
10. 3.9% of patients were considered as atypical and requires further 
follow up and investigations.  
 
11. Demyelinating disease in association with ON was less common in 
our study. 
 
Visual function following optic neuritis treatment showed good 
recovery.  There was less incidence of associated demyelination  in our 
study.  
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PROFORMA 
VISUAL OUTCOME FOLLOWING OPTIC NEURITIS 
TREATMENT 
Name _______________________      
  
Age           Mr.No. 
Gender      M –Male, F- Female 
Chief complaints 
Onset of symptoms 
Laterality    1. RE ___________ 
     2. LE ___________ 
Defective vision   RE  1. Present 
     LE  2. Absent 
Pain on Eye Movements    1. Present 
       2. Absent 
Headache      1. Present 
       2. Absent 
Double Vision     1. Present 
       2. Absent 
 
 
OCULAR EXAMINATION: 
     RE  LE  1.6/6 – 6/60 
BCVA        2.6/60 – 1/60 
         3.<1/60 
PUPIL 
A) Direct 
B) Indirect       1. Present 
C) RAPD        2. Absent 
EOM          1. Full 
         2. Restricted 
         3. Others 
CLINICAL INVESTIGATION: 
     RE  LE 
Colour Vision       1. Normal 
         2. Defective 
 
Red Color Desaturation       1.100% 
         2. <100% 
 
Brightness Sensitivity      1. 100% 
         2. <100 
 
 
 
 
 
FUNDUS 
     RE  LE 
Normal         1. Yes 
          2. No 
Disc Edema  
Hyperemia       
Splinter Haemorrhage  1. Present 
Temporal Pallor                2. Absent 
Primary Optic Atrophy 
Secondary Optic Atrophy  
CENTRAL FIELDS 
     RE  LE 
Normal         1. Yes 
          2. No 
Enlargement of Blind Spot  
Central Scotoma   1. Present 
Centrocaecal Scotoma        2. Absent 
Altitudinal Hemianopia  
 
 
NEUROLOGICAL EXAMINATION 
Higher Functions 1. Normal 
Cranial Nerves         2. Affected 
Investigations 
TC 
DC 
ESR 
Mantoux 
TPHA 
Platelet Count 
TREATMENT 
Medical  1. IV Steroids 
   2. Oral Steroids 
1st Follow  Up   (15 days) 
    RE  LE 
BCVA   
Colour Vision 
 
 
 
 
 
FUNDUS  
     RE  LE 
Normal         1. Yes 
          2. No 
Disc Edema  
Hyperemia       
Splinter Haemorrhage  1. 
Present 
Temporal Pallor           2. 
Absent 
Primary Optic Atrophy 
Secondary Optic Atrophy  
CENTRAL FIELDS 
     RE  LE 
Normal         1. Yes 
          2. No 
Enlargement of Blind Spot  
Central Scotoma   1. Present 
Centrocaecal Scotoma        2. Absent 
 
 
Altitudinal Hemianopia  
2nd  Follow  Up   (1 Month) 
    RE  LE 
BCVA   
Colour Vision 
FUNDUS  
     RE  LE 
Normal         1. Yes 
          2. No 
Disc Edema  
Hyperemia       
Splinter Haemorrhage  1. 
Present  
Temporal Pallor          2. 
Absent 
Primary Optic Atrophy 
Secondary Optic Atrophy  
 
 
 
 
CENTRAL FIELDS 
     RE  LE 
Normal         1. Yes 
          2. No 
Enlargement of Blind Spot  
Central Scotoma   1. Present 
Centrocaecal Scotoma        2. Absent 
Altitudinal Hemianopia  
 
 
 
 
  
 
 
ABBREVATIONS 
 
ON   – Optic neuritis 
MS   –  Multiple sclerosis 
NFL   –  Nerve fibre layer 
ONTT  –  Optic neuritis treatment trial 
LONS  –  Longitudinal optic neuritis study 
CHAMPS  –   Controlled High Risk Avonex Multiple Sclerosis 
Trial. 
BENEFIT –    Beta Interferon In Newly Emerging MS for Initial  
Treatment. 
ETOMS  –  Early Treatment of Multiple Sclerosis Study 
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alagu 42 female 3599729 re 1 1week present present absent absent re1/60 1/60 RAPD Full poor vision cant do cant do NORMAL disc edema cant do 6/9 normal centrocaecal temporal pallor reduced reduced
ammutha 30 female 3501647 le 2 5 days present absent absent absent le-PL PL RAPD Full poor vision poor vision poor vision NORMAL temporal pallor poor vision pl poor vision poor vision poa reduced reduced
anna mary 50 female 3398333 le 2 2 months present absent absent absent le-pl PL RAPD Full poor vision poor vision poor vision NORMAL temporal pallor poor vision fcf cant do poor vision mild temporal pallor poor vision poor vision
arockia mary 55 male 3703479 le 2 1 week present present absent absent le-1/2/60 1/2/60 RAPD Full poor vision poor vision poor vision NORMAL disc edema poor vision 6/6 normal normal resolving disc edema Normal Normal
arumugam 54 male 3647974 re 1 5 days present absent absent absent 6/18p 6/18p normal Full 12/21 reduced reduced NORMAL disc edema centrocaecal scotoma 6/9 normal normal resolving disc edema reduced reduced
babitha 28 female 3717571 re 1 10days absent present absent absent re-6/6p 6/6p normal Full 21/21 1 1 NORMAL normal normal 6/6 normal normal normal Normal normal
bagavathi 62 female 3505097 le 2 3 weeks present absent absent absent le-FCF FCF RAPD Full poor vision poor vision poor vision NORMAL temporal pallor poor vision 6/36 normal centrocaecal mild temporal pallor Normal normal
balasubramani 29 male 3153282 re 1 15 days present absent absent absent be-6/18 6/18 RAPD Full 1/21 reduced reduced NORMAL normal centrocaecal scotoma 6/6 normal centrocaecal normal Normal Normal
balasubramani 3153282 le 2 present absent absent 6/18 RAPD Full 1/21 reduced reduced NORMAL normal centrocaecal scotoma 6/9 normal centrocaecal normal Normal Normal
baskar 57 male 3678489 le 2 5 days present absent absent absent le-1/2/60 1/2/60 RAPD Full poor vision cant do cant do NORMAL disc hyperemia/edema poor vision 6/9 normal normal normal Normal Normal
boomika 24 female 3525766 re 1 1 month present absent absent present re-6/36 le-6/36 6/36 RAPD Full 12/21 reduced reduced NORMAL normal centrocaecal scotoma 6/18 normal poor vision mild hyperemia reduced reduced
boomika 3525766 le 2 present absent present 6/36 RAPD Full 12/21 reduced reduced NORMAL disc hyperemia centrocaecal scotoma 6/18 normal normal normal Normal Normal
boopathi 22 male 3508994 re 1 1week present present absent present le-2/60 2/60 RAPD Full 0/21 reduced reduced NORMAL normal poor vision 6/6 normal normal normal Normal Normal
chandrasekar 52 male 3465445 re 1 1week present absent absent absent re-6/60 6/60 RAPD Full 12/21 reduced reduced NORMAL disc edema centrocaecal scotoma 6/18 normal normal mild temp.pallor reduced reduced
chellamuthu 50 male 3551406 le 2 3days present absent absent absent le-3/60 3/60 RAPD Full 0/21 cant do cant do NORMAL disc hyperemia/edema cant do 6/6p normal normal resolved disc edema Normal Normal
chellathal 50 female 3545763 re 1 20 days present absent absent present re-1/60 1/60 RAPD Full cant do cant do cant do NORMAL temporal pallor cant do 4/60 defective sup/inf defect pri. OA reduced reduced
damodaran 35 male 3347392 le 2 4days present absent absent absent le-fcf FCF RAPD Full cant do cant do cant do NORMAL disc edema poor vision 6/12 defective normal temporal pallor reduced reduced
dhanalakshmi 27 female 3557659 le 2 20 days present present absent absent re-fcf FCF RAPD Full cant do cant do cant do NORMAL disc hyperemia poor vision 6/6p normal centrocaecal normal Normal normal
ganesan 45 male 3562830 le 2 1week present absent present absent le-4/60 4/60 RAPD Full 1/10 defective defective NORMAL disc edema not done 6/12 normal normal temporal pallor Normal Normal
gangadaram 35 male 3657932 le 2 10 days present absent absent absent le-5/60 5/60 RAPD Full 2/21 reduced reduced NORMAL disc edema centrocaecal scotoma 6/24 normal normal resolving disc edema Normal Normal
gokila 21 female 3568642 re 1 2days present absent absent present re-pl PL RAPD Full poor vision reduced <100% NORMAL disc hyperemia poor vision 6/6p normal normal normal Normal Normal
gokilavani 36 female 3721671 le 2 3days absent present absent absent le- 6/6p 6/6p normal Full 13/21 reduced >50% NORMAL normal centrocaecal scotoma 6/6 normal normal normal Normal Normal
gunavathi 22 female 3627579 le 2 4days absent present absent present le-6/6 6/6 normal Full 21/21 1 1 NORMAL normal normal
iyyammal 50 female 3624310 le 2 10 days present absent absent absent le-hm HM RAPD Full poor vision cant do cant do NORMAL disc edema poor vision 2/60 cant do poor vision hyperemia d.edema poor vision poor vision
jeganath 35 male 3684806 le 2 2 days absent present absent absent le-6/6 6/6 RAPD Full 21/21 1 1 NORMAL disc edema normal
juliet 39 female 3633617 le 2 1month present absent absent absent le-6/36 6/36 RAPD Full 21/21 1 1 NORMAL disc edema normal 6/24p normal normal normal Normal Normal
kalaivanan 37 male 3685404 le 2 1 day present absent absent absent NOPL RAPD Full poor vision poor vision poor vision NORMAL disc hyperemia/edema poor vision 6/36 normal centrocaecal resolving disc edema reduced reduced
kalaivanan 3685404 re 1 present absent absent be-pl+ no pl PL RAPD Full poor vision poor vision poor vision NORMAL disc hyperemia/edema poor vision 6/36 defective centrocaecal resolving disc edema reduced reduced
kalyani 40 male 3701843 le 2 6days present absent absent absent le- 3/60 3/60 RAPD Full cant do cant do cant do NORMAL disc edema centrocaecal scotoma 6/12 normal normal resolving disc edema Normal Normal
kamalahasan 33 male 3647584 re 1 10 days present absent absent absent re-1/60 1/60 RAPD Full 0/21 cant do cant do NORMAL disc hyperemia poor vision
karmegam 60 male 3533665 le 2 5days present absent absent present re-4/60 le-fcf 4/60 RAPD Full poor vision defective nil NORMAL disc edema Poor vision 1/60 not done diffuse constriction temporal pallor reduced reduced
karuppasamy 27 male 3477145 le 2 10 days present present absent present le-5/60 5/60 RAPD Full 0/21 reduced <100% NORMAL disc edema poor vision 6/6p normal normal resolving disc edema Normal Normal
karuppiah 64 male 3418305 le 2 20 days present present present absent le-1/60 1/60 RAPD Full poor vision poor vision 0.3 NORMAL disc edema centrocaecal scotoma 6/9 normal normal mild hyperemia Normal Normal
leelavathi 43 female 3614240 re 1 10 days present absent absent absent re-pl PL RAPD Full poor vision cant do cant do NORMAL temporal pallor poor vision hm poor vision poor vision mild temporal pallor poor vision poor vision
mahabu nisha 32 male 3695795 re 1 15 days present absent present absent be-6/12 6/12 normal Full 16/21 1 1 NORMAL disc edema normal 6/6 normal normal temporal pallor Normal Normal
mahabu nisha 3695795 le 2 present absent absent 6/12 normal Full 13/21 1 1 NORMAL disc edema normal 6/6 normal normal resolving disc edema Normal Normal
malaiammal 62 female 3706114 le 2 4 days present absent absent HM RAPD Full poor vision poor vision poor vision NORMAL temporal pallor Poor vision 6/18 normal centrocaecal temporal pallor reduced reduced
malaiammal 3706114 re 1 present absent absent absent re-6/60 le-hm 6/60 RAPD Full 12/21 poor vision poor vision NORMAL temporal pallor enlargement of blind spot 6/12 normal arcuate scotoma temporal pallor reduced reduced
mallika 50 male 3697246 le 2 6 days present absent absent absent le-pl PL normal Full poor vision poor vision poor vision NORMAL disc edema poor vision 6/24 normal normal temporal pallor Normal Normal
manjula 50 female 3522601 re 1 4 days present absent absent present re-6/60 6/60 RAPD Full 9/21 reduced reduced NORMAL disc hyperemia poor vision 6/6 normal normal resolved disc edema Normal Normal
mariammal 55 female 3532296 le 2 3days present absent absent present le-pl PL RAPD Full poor vision poor vision defective NORMAL temporal pallor poor vision 6/24 normal centrocaecal temporal pallor Normal Normal
mariammal 50 female 3560236 re 1 2weeks present present absent absent re-5/60 5/60 RAPD Full 13/21 reduced reduced NORMAL temporal pallor centrocaecal scotoma 6/24p normal centrocaecal temporal pallor reduced reduced
meenakshi 40 female 3625372 le 2 1week present absent present absent re-HM HM RAPD Full cant do cant do cant do NORMAL disc edema poor vision
meenal 31 female 3707447 le 2 2 weeks absent present absent absent le-6/6p 6/6p normal Full 21/21 1 1 NORMAL normal temporal field defect
moshe 45 male 3678815 re 1 20 days present absent absent absent re-pl PL RAPD Full poor vision cant do cant do NORMAL temporal pallor poor vision pl poor vision poor vision gross t.pallor poor vision poor vision
murugan 30 male 3287750 re 1 20days present absent absent absent re-1/60 1/60 RAPD Full cant do cant do cant do NORMAL disc edema cant do 6/6p normal normal mild hyperemia Normal Normal
murugan.s 50 male 3380620 le 2 1week present absent absent absent le-6/18p 6/18p RAPD Full 14/21 reduced reduced NORMAL hyperemia disc edema centrocaecal scotoma 6/60 defective altitudinal mild hyperemia re.d .edema reduced reduced
muthuirulayee 26 female 3647927 re 1 2 days present absent absent present re-5/60 5/60 RAPD Full 1/21 cant do cant do NORMAL disc edema centrocaecal scotoma
muthupetchi 60 female 3590767 re 1 1 month present present absent absent re-1/60 1/60 RAPD Full cant do cant do cant do NORMAL temporal pallor cant do 1/60 defective poor vision temporal pallor reduced reduced
nagalingam 35 male 3626116 le 2 10 days present absent absent present le-2/60 2/60 RAPD Full poor vision cant do reduced NORMAL disc hyperemia cant do
nagaraj 28 male 3530513 le 2 3days absent present absent present le-6/6 6/6 RAPD Full 14/21 reduced reduced NORMAL normal centrocaecal scotoma 6/6p normal normal normal Normal Normal
nithya 30 male 3683413 le 2 15 days present absent absent absent le-3/60 3/60 RAPD Full poor vision poor vision poor vision NORMAL temporal pallor poor vision
padmavathy 33 female 3393963 le 2 1month present absent absent present le-PL PL RAPD Full poor vision poor vision poor vision NORMAL disc edema poor vision 6/36 normal normal resolving disc edema Normal Normal
palaniammal 42 female 3629294 re 1 4 days present absent absent absent be-1/60 1/60 RAPD Full cant do cant do cant do NORMAL disc edema enlargement of blind spot 6/18 normal normal mild hyperemia resol d.edema Normal Normal
palaniammal 3629294 le 2 present absent absent 1/60 RAPD Full cant do cant do cant do NORMAL disc edema enlargement of blind spot 6/24 normal normal temporal pallor Normal Normal
pandiammal 42 female 3408493 re 1 1month present present absent present le-2/60 2/60 RAPD Full poor vision poor vision poor vision NORMAL normal centrocaecal scotoma 6/12 normal normal normal Normal Normal
parameswari 50 female 3462579 re 1 1week present present absent absent re-fcf  le-2/60 FCF RAPD Full poor vision poor vision poor vision NORMAL temporal pallor generalized constriction 6/24 normal sup/inf defect early temporal pallor reduced reduced
parameswari 3462579 le 2 present 2/60 RAPD Full poor vision poor vision poor vision NORMAL temporal pallor Poor vision 6/9 normal sup/inf defect early temporal pallor reduced reduced
paul ananth 44 male 3607237 le 2 2 days present present absent absent le-6/18p 6/18p RAPD Full 14/21 reduced reduced NORMAL normal normal
periyakamatchi 64 male 3565711 le 2 4days present absent absent present pl PL RAPD Full cant do cant do poor vision NORMAL temporal pallor poor vision 1/60 defective poor vision early t.pallor poor vision poor vision
ponnusamy 20 male 3561080 re 1 20 days present absent absent absent re-pl PL RAPD Full cant do cant do poor vision NORMAL temporal pallor poor vision pl defective poor vision pri. OA poor vision poorvision
rabika banu 25 female 3623624 re 1 4days absent present absent absent re-6/6p 6/6p normal Full 21/21 1 1 NORMAL disc hyperemia/edema normal 6/6 normal normal resolving disc edema Normal Normal
rajasekaran 54 male 3499171 le 2 3 days present present absent 2/60 RAPD Full poor vision cant do poor vision NORMAL disc edema Superior field loss
rajasekaran 3499171 re 1 present present present absent re-1/60le-2/60 1/60 RAPD Full poor vision cant do poor vision NORMAL disc edema Paracentral scotoma
rajeswari 22 female 3624278 re 1 1week present absent absent absent re-4/60 4/60 normal Full poor vision poor vision poor vision NORMAL disc edema poor vision
raman 45 male 3541113 le 2 4days present absent absent le-fcf FCF RAPD Full poor vision defective poor vision NORMAL temporal pallor poor vision 6/6p normal poor vision  early temporal pallor Normal Normal
ramawsamy 24 male 3714091 re 1 2 days present absent absent absent re-4/60 4/60 RAPD Full 0/21 reduced poor vision NORMAL disc edema centrocaecal scotoma
ramuthai 64 female 3401322 re 1 3months present absent absent absent le-pl PL RAPD Full cant do cant do poor vision NORMAL temporal pallor poor vision 5/60 defective central scotoma mild temporal pallor reduced reduced
revathy 3517695 le 2 present absent absent FCF RAPD Full poor vision poor vision poor vision NORMAL disc edema poor vision 6/6 normal mild hyperemic resol d.edema Normal Normal
revathy 29 female 3517695 re 1 1 week present absent absent absent RE-FCF LE FCP FCF RAPD Full poor vision poor vision poor vision NORMAL disc edema poor vision 6/6 normal normal resolved disc edema Normal Normal
rober rajkumar 50 male 3446034 le 2 2days present present absent present le-6/36 6/36 RAPD Full reduced reduced NORMAL disc hyperemia centrocaecal scotoma 6/9 normal normal mild hyperemia Normal Normal
samuel 24 male 3689941 re 1 10 days present present absent absent re-6/9p 6/9p RAPD Full 1/21 reduced reduced NORMAL disc edema enlargement of blind spot
sangeetha 30 female 3483052 le 2 1month present present present absent le-6/6 6/6 RAPD Full 21/21 1 1 NORMAL disc edema centrocaecal scotoma 1/2/60 poor vision poor vision temporal pallor poor vision poor vision
sangumuthu 42 male 3696406 le 2 4 days present present absent absent le-1/60 1/60 RAPD Full poor vision cant do cant do NORMAL normal normal 6/6 normal normal normal Normal Normal
saravani 23 female 3637929 re 1 3 days present absent present absent re-1/2/60 1/2/60 normal Full 0/21 poor vision poor vision NORMAL disc edema poor vision
sathish 29 male 3582982 le 2 20 days present absent absent absent le-hm HM RAPD Full poor vision poor vision poor vision NORMAL disc hyperemia poor vision 6/9 normal centrocaecal hyperemia Normal Normal
sathiya rama 60 female 3652178 le 2 20 days present absent absent absent le-pl PL RAPD Full poor vision poor vision cant do NORMAL temporal pallor mild edema poor vision 1/2/60 cant do poor vision temporal pallor reduced reduced
satinder singh 25 male 3650563 le 2 2weeks present absent absent absent le-6/60 6/60 RAPD Full 2/21 reduced reduced NORMAL disc edema inferior and sup field defect 6/6p normal normal normal Normal Normal
selvam 60 male 3700221 re 1 10 days present absent present absent re-pl+ PL RAPD Full poor vision poor vision poor vision NORMAL disc edema poor vision 3/60 poor vision central scotoma normal reduced reduced
shanmugam 41 male 3429775 le 2 15 days present present absent present le-6/24 6/24 RAPD Full 21/21 reduced reduced NORMAL disc hyperemia normal 6/9 normal normal normal Normal Normal
sivakumar 41 male 3716211 re 1 13days present absent absent absent re- 6/60 6/60 RAPD Full 3/21 reduced reduced NORMAL disc edema centrocaecal scotoma
sulaika 45 female 3710301 le 2 3 weeks present absent absent absent le-hm HM RAPD Full poor vision poor vision poor vision NORMAL disc edema poor vision
surendar 22 male 3600660 le 2 7 days present absent absent absent le-5/60 5/60 RAPD Full 1/21 reduced reduced NORMAL disc hyperemia/edema defective 6/12 normal poor vision resolved disc edema reduced reduced
suresh 22 male 3513263 le 2 3days present present absent present le-1/60 1/60 RAPD Full 0/21 poor vision poor vision NORMAL disc edema generalised 6/6 normal normal resolving disc edema Normal Normal
tamilarasi 32 female 2782001 re 1 2 days present absent absent absent re-fcf FCF RAPD Full poor vision cant do cant do NORMAL disc edema poor vision pl poor vision poor vision hyperemia d.edema reduced reduced
teena paul 42 female 3521274 re 1 3 weeks present present absent absent re- 6/6 6/6 normal Full 21/21 1 1 NORMAL normal centrocaecal scotoma 6/6 normal normal normal Normal Normal
umadevi 36 female 3281551 re 1 20 days present absent absent absent re-3/60 3/60 RAPD Full 1/21 reduced poor vision NORMAL disc edema poor vision
vanaja 45 female 3621081 le 2 10 days present absent absent absent le-6/18p 6/18p RAPD Full 0/21 reduced reduced NORMAL temporal pallor centrocaecal scotoma
veeranan 62 male 3559839 re 1 1week present absent absent absent re-6/18 6/18 RAPD Full 21/21 1 1 NORMAL normal centrocaecal scotoma 6/9 normal centrocaecal normal Normal Normal
veeravel 61 male 3631863 le 2 4days present present absent absent le-6/36 6/36 RAPD Full 0/21 reduced reduced NORMAL normal peripheral loss 6/12 normal poor vision normal Normal Normal
vellaiyammal 55 female 3628515 le 2 1 month present present present absent le-4/60 4/60 RAPD Full 0/21 cant do poor vision NORMAL disc edema altitudinal field defect 4/60 poor vision poor vision mild temporal pallor reduced reduced
velmurugan 30 male 3562834 le 2 2days absent present absent absent le-6/36 6/36 RAPD Full 21/21 1 1 NORMAL disc edema normal 6/6p normal normal normal Normal Normal
velu 40 male 3568511 re 1 1week present absent absent present re-6/60 6/60 RAPD Full 10/21 reduced reduced NORMAL disc edema Paracentral scotoma 6/12 normal centrocaecal mild temporal pallor Normal Normal
veni 30 female 3557795 re 1 2 days present absent absent absent re-hm HM RAPD Full cant do poor vision poor vision NORMAL disc edema poor vision 1/2/60 defective poor vision mild temporal pallor reduced reduced
venketeswari 28 female 3714825 le 2 7 days present absent present absent le-1/2/60 1/2/60 RAPD Full 0/21 reduced poor vision NORMAL disc edema poor vision
vijayan 35 male 3573475 le 2 20days present absent absent absent le-1/60 1/60 RAPD Full 0/21 reduced poor vision NORMAL temporal pallor poor vision 6/60 defective sup/inf defect mild temporal pallor reduced reduced
yasmin 25 male 3511227 re 1 5days present absent present absent re-3/60 le-pl 3/60 RAPD Full poor vision poor vision poor vision NORMAL hyperemic disc edema Central scotoma 6/60 defective central resolving disc edema reduced reduced
yasmin 3511227 le 2 present absent absent PL RAPD Full poor vision poor vision poor vision NORMAL hyperemia/ disc edema Poor vision 6/24 normal centrocaecal mild hyperemia reduced reduced
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
